Papers
8
Total Citations
247
H-Index
7
About
Dr. Ava Saidian is a pioneering urologic surgeon and researcher whose work is reshaping the surgical management of urologic cancers, particularly through the lens of robotic innovation. Her primary research focuses on comparing the safety and efficacy of single-port (SP) versus multi-port robotic platforms for radical prostatectomy and partial nephrectomy. In her landmark 2020 study (59 citations), she provided the first single-institutional evidence that the da Vinci SP system offers comparable perioperative outcomes to the multi-port Xi system for prostate cancer, challenging established surgical dogma. Dr. Saidian has further demonstrated that SP robotic partial nephrectomy reduces analgesic requirements without compromising oncologic safety (46 citations). Her multicenter, propensity-score matched analysis (38 citations) critically assessed the trade-off between off-clamp techniques and functional outcomes in complex renal masses, providing surgeons with evidence-based guidance for high-RENAL score tumors. Through her leadership in the ROBUUST registry, she has advanced understanding of lymph node dissection in upper tract urothelial carcinoma (29 citations). With over 240 total citations across her portfolio, Dr. Saidian is a leading voice in the transition toward less invasive, more patient-centered robotic surgery, and her narrative reviews on renal cell carcinoma management have become essential reading for trainees navigating the rapidly evolving landscape of urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8